Enanta Pharmaceuticals (NASDAQ:ENTA) Downgraded by StockNews.com to “Sell”

StockNews.com downgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) from a hold rating to a sell rating in a report released on Thursday morning.

A number of other research firms have also commented on ENTA. SVB Leerink decreased their price target on Enanta Pharmaceuticals from $58.00 to $44.00 and set a market perform rating on the stock in a research report on Thursday, May 19th. Robert W. Baird decreased their price target on Enanta Pharmaceuticals from $130.00 to $90.00 and set an outperform rating on the stock in a research report on Thursday, May 19th. Oppenheimer reduced their price objective on Enanta Pharmaceuticals from $70.00 to $45.00 and set an outperform rating on the stock in a report on Friday, May 20th. JMP Securities reaffirmed a buy rating and set a $103.00 price objective on shares of Enanta Pharmaceuticals in a report on Wednesday. Finally, Roth Capital reduced their price objective on Enanta Pharmaceuticals from $101.00 to $70.00 in a report on Wednesday, May 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $74.14.

ENTA stock opened at $45.67 on Thursday. Enanta Pharmaceuticals has a 1-year low of $37.59 and a 1-year high of $102.00. The firm has a market cap of $945.96 million, a P/E ratio of -8.27 and a beta of 0.67. The business’s 50 day moving average is $50.94 and its 200-day moving average is $62.06.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last released its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.20). The business had revenue of $18.72 million for the quarter, compared to the consensus estimate of $20.40 million. Enanta Pharmaceuticals had a negative return on equity of 28.80% and a negative net margin of 122.68%. During the same quarter last year, the company earned ($1.09) earnings per share. On average, research analysts expect that Enanta Pharmaceuticals will post -5.56 earnings per share for the current fiscal year.

In other news, VP Nathalie Adda sold 32,785 shares of the stock in a transaction on Monday, April 4th. The stock was sold at an average price of $72.18, for a total value of $2,366,421.30. Following the transaction, the vice president now owns 34,982 shares of the company’s stock, valued at approximately $2,525,000.76. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 11.74% of the company’s stock.

Several hedge funds have recently bought and sold shares of ENTA. RA Capital Management L.P. acquired a new position in shares of Enanta Pharmaceuticals in the 1st quarter valued at $68,633,000. Deep Track Capital LP bought a new stake in shares of Enanta Pharmaceuticals in the 1st quarter valued at $14,146,000. Invesco Ltd. increased its position in shares of Enanta Pharmaceuticals by 173.0% in the 4th quarter. Invesco Ltd. now owns 289,844 shares of the biotechnology company’s stock valued at $21,674,000 after buying an additional 183,676 shares in the last quarter. State Street Corp increased its position in shares of Enanta Pharmaceuticals by 16.1% in the 1st quarter. State Street Corp now owns 1,308,586 shares of the biotechnology company’s stock valued at $93,145,000 after buying an additional 181,517 shares in the last quarter. Finally, Darwin Global Management Ltd. bought a new stake in shares of Enanta Pharmaceuticals in the 4th quarter valued at $12,428,000. 98.87% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Company Profile (Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

See Also

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Want More Great Investing Ideas?

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.